With the introduction of biologics to rheumatoid arthritis, tocilizumab (TCZ), a humanised anti‐interleukin (IL)‐6 receptor (IL‐6R) monoclonal antibody, is a promising agent in various autoimmune diseases, such as large vessel vasculitis (giant cell arteritis and Takayasu arteritis) and adult‐onset Still's disease.1, 2, 3. Here, IL6R is linked to autoimmune disease.